Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Breaking Down the Data in Genitourinary, Gastrointestinal, and Breast Cancers, Plus Sarcoma and Melanoma at ASCO 2023: Drs Rini, Lewis, Trent, Luke, Kunz, and Lustberg

June 6th 2023

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across hematologic oncology during the conference.

Cabozantinib/Atezolizumab Combo Misses PFS, OS End Points in ICI-Treated, Advanced RCC

June 5th 2023

The addition of atezolizumab to cabozantinib did not improve progression-free survival or overall survival vs cabozantinib alone in patients with advanced renal cell carcinoma who previously received treatment with an immune checkpoint inhibitor, missing the primary end points of the phase 3 CONTACT-03 trial.

Multidisciplinary Strategies in RCC Management: Future Directions in Care

June 5th 2023

Closing out their discussion on renal cell carcinoma, key opinion leaders highlight the value of multidisciplinary care and look toward future evolutions in the treatment paradigm.

Scenario 3: A 44-Year-Old Woman With RCC at Intermediate-High Risk for Recurrence

June 5th 2023

Expert panelists highlight aspects of a final patient scenario, discussing adjuvant treatment strategies in the setting of renal cell carcinoma at intermediate-high risk for recurrence.

Cabozantinib Plus Nivolumab and Ipilimumab Elicits Meaningful Activity in RCCvh

June 3rd 2023

Triplet therapy with cabozantinib, nivolumab, and ipilimumab demonstrated clinical meaningful activity in patients with renal cell carcinoma with variant histologies.

Belzutifan/Lenvatinib Elicits Responses in Advanced ccRCC After Progression on ICI and VEGF TKI

June 3rd 2023

Belzutifan plus lenvatinib generated responses and displayed a manageable safety profile in patients with advanced clear cell renal cell carcinoma whose disease progressed following treatment with a PD-1/L1 inhibitor and a VEGF TKI.

Dr Srour on Next Steps Planned for the Investigation of ALLO-316 in Advanced Clear Cell RCC

June 2nd 2023

Samer A. Srour, MB ChB, MS, discusses planned next steps and future avenues of investigation for the novel CD70-targeted agent ALLO-316 in patients with advanced or metastatic clear cell renal cell carcinoma.

Dr King on Teratoma in Residual Nonretroperitoneal Disease After Chemotherapy for Testicular Cancer

June 1st 2023

Jennifer M. King, MD, discusses results from a retrospective study on the prevalence of teratoma and active germ cell tumors in patients who have residual nonretroperitoneal disease following chemotherapy for nonseminomatous germ cell tumors, and what these findings indicate about the need for surgical resection in this patient population.

ASCO 2023 Insights: ADCS, Next-Generation TKIs, and More Lead Data Pack Ahead of Annual Meeting

May 31st 2023

Experts in the field share the abstracts they found to be the most practice changing at this year’s ASCO Annual meeting.

Combination IO TKI Therapy in Patients With Metastatic Renal Cell Carcinoma

May 29th 2023

Focused discussion on combination IO-TKI therapy and its role as first-line therapy in patients diagnosed with metastatic renal cell carcinoma.

Scenario 2: A 59-Year-Old Man With Favorable Risk Metastatic RCC

May 29th 2023

Moving on to the second patient scenario of renal cell carcinoma, panelists reflect on the treatment pathway for favorable risk metastatic disease.

Dr Tsao on the Role of Nivolumab Plus Cabozantinib in Advanced RCC

May 24th 2023

Che-Kai Tsao, MD, discusses key updates from the phase 3 CheckMate 9ER trial, and how these data clarify the role of nivolumab plus cabozantinib as a new standard of care in renal cell carcinoma.

Dr Zhang on the Rationale for Investigating Sintilimab/Axitinib in FH-Deficient RCC

May 23rd 2023

Xingming Zhang, MD, discusses the rationale for investigating the combination of sintilimab and axitinib in patients with advanced fumarate hydratase-deficient renal cell carcinoma in a phase 2 trial.

Sintilimab/Axitinib Combo Shrinks FH-Deficient RCC Tumors

May 23rd 2023

Xingming Zhang, MD, discusses unmet needs in fumarate hydratase–deficient renal cell carcinoma; shares key efficacy, safety, and quality of life findings from a phase 2 trial of sintilimab plus axitinib; and elaborates on the next steps for this research, including an analysis of biomarkers and potential resistance mechanisms.

Dr Srour on the Mechanism of Action of ALLO-316 in Metastatic Clear Cell RCC

May 22nd 2023

Samer A. Srour, MB ChB, MS, discusses the mechanism of action of ALLO-316, which is being investigated for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma, and details safety findings from the phase 1 TRAVERSE study evaluating ALLO-316 in this patient population.

OncLive Honors 12 Cancer Care Pioneers

May 22nd 2023

For the 11th consecutive year, OncLive is honored to recognize oncology leaders whose innovations have contributed to immeasurable improvements in outcomes for countless patients.

Role of Combination Immunotherapy in Metastatic Renal Cell Carcinoma

May 22nd 2023

Key opinion leaders in the field of renal cell carcinoma management discuss the advent of combination immunotherapy in patients with metastatic disease.

Scenario 1: A 47-Year-Old Man With Intermediate Risk Metastatic RCC

May 22nd 2023

Expert perspectives on a patient scenario of intermediate risk metastatic renal cell carcinoma and corresponding management with combination immunotherapy.

Cabozantinib Plus Nivolumab and Ipilimumab Provides PFS Benefit in Advanced RCC

May 20th 2023

The addition of cabozantinib to nivolumab and ipilimumab led to improved progression-free survival vs nivolumab and ipilimumab alone in patients with treatment-naïve advanced renal cell carcinoma; however, the rate of grade 3/4 adverse effects with the triplet was 79%.

Dr Rini on the OPTIC RCC Trial in Advanced Kidney Cancer

May 19th 2023

Brian I. Rini, MD, FASCO, discusses efforts to utilize genetic testing to improve treatment selection in renal cell carcinoma through the phase 2 OPTIC RCC trial.